IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION May 2026 Update Filed in 2016 and centralized in the Eastern District of Pennsylvania, the Generic Pharmaceuticals Pricing Antitrust Litigation (MDL No. 2724) remains one of the largest and most complex antitrust cases in the U.S. The litigation alleges that multiple generic drug manufacturers conspired to fix prices, allocate markets, and limit competition across hundreds of generic drugs. Current Status (2026) This

Over $115.2 Million via Pharmaceutical Benefit Plan Settlements, separate from the Generic Pharmaceuticals Pricing Antitrust Litigation. Overview There are typically several active lawsuits and/or class action settlements that fall into the category of “pharmaceutical benefit plan settlements.” Under these cases, it is generally alleged that businesses with self-insured health plans overpaid for drugs purchased on behalf of their employees due to artificially inflated and/or

Update: Preliminary approval has been granted (March 20, 2026) for a new Acute Care Hospital Opioids Settlement in San Miguel Hospital Corp., et al. v. Richard Sackler, et al. (D.N.M.), establishing a settlement fund of approximately $174.2 million . This settlement represents an additional recovery opportunity specifically for Acute Care Hospitals, stemming from allegations that members of the Sackler family and related entities contributed to the opioid epidemic and the

For most merchants, payment processing is just part of doing business—until the costs start adding up. What many don’t realize is that they may be entitled to recover a portion of the fees they’ve already paid. Every transaction carries layers of expense—interchange fees, network fees, processor markups, and compliance costs—that quietly erode margins over time. These costs are often accepted as fixed. They’re not. Many of these practices have been challenged in court, creati